Key Points
- COO Jennifer Champoux sold 2,175 shares of Monte Rosa Therapeutics (NASDAQ: GLUE) at an average price of $20.00, totaling $43,500. After the sale, she still held 62,371 shares valued at about $1.25 million.
- The stock has been volatile but remains elevated, opening at $19.39 with a 52-week range of $3.90 to $25.77 and a market cap of $1.64 billion. It also trades near its 50-day and 200-day moving averages around $18.1.
- Recent earnings missed expectations, with the company reporting a loss of $0.45 per share versus the expected $0.39 loss and revenue of $4.21 million versus $10.95 million expected. Analysts currently rate the stock a moderate buy with a consensus price target of $32.50.
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) COO Jennifer Champoux sold 2,175 shares of the stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $20.00, for a total transaction of $43,500.00. Following the completion of the sale, the chief operating officer owned 62,371 shares of the company's stock, valued at approximately $1,247,420. This trade represents a 3.37% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Monte Rosa Therapeutics Stock Performance
NASDAQ:GLUE opened at $19.39 on Friday. The firm has a market cap of $1.64 billion, a price-to-earnings ratio of -13.10 and a beta of 1.62. Monte Rosa Therapeutics, Inc. has a 52 week low of $3.90 and a 52 week high of $25.77. The firm has a 50-day moving average price of $18.12 and a two-hundred day moving average price of $18.16.
Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.06). The firm had revenue of $4.21 million during the quarter, compared to analysts' expectations of $10.95 million. Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 40.99%. As a group, sell-side analysts forecast that Monte Rosa Therapeutics, Inc. will post -1.23 earnings per share for the current year.
Institutional Investors Weigh In On Monte Rosa Therapeutics
Several large investors have recently modified their holdings of GLUE. State Street Corp increased its stake in shares of Monte Rosa Therapeutics by 148.9% during the 4th quarter. State Street Corp now owns 2,107,480 shares of the company's stock worth $33,045,000 after purchasing an additional 1,260,707 shares during the last quarter. MPM Bioimpact LLC purchased a new stake in shares of Monte Rosa Therapeutics during the 4th quarter worth approximately $18,399,000. AQR Capital Management LLC increased its stake in shares of Monte Rosa Therapeutics by 459.4% during the 2nd quarter. AQR Capital Management LLC now owns 1,283,942 shares of the company's stock worth $5,791,000 after purchasing an additional 1,054,406 shares during the last quarter. Braidwell LP purchased a new stake in shares of Monte Rosa Therapeutics during the 4th quarter worth approximately $14,870,000. Finally, Vestal Point Capital LP purchased a new stake in shares of Monte Rosa Therapeutics during the 3rd quarter worth approximately $5,928,000. Hedge funds and other institutional investors own 79.96% of the company's stock.
Analyst Upgrades and Downgrades
Several equities research analysts have commented on the stock. Wells Fargo & Company decreased their price objective on shares of Monte Rosa Therapeutics from $30.00 to $29.00 and set an "overweight" rating for the company in a research note on Wednesday, March 18th. Guggenheim reduced their target price on shares of Monte Rosa Therapeutics from $34.00 to $30.00 and set a "buy" rating for the company in a research report on Wednesday, March 18th. JPMorgan Chase & Co. raised their price target on shares of Monte Rosa Therapeutics from $30.00 to $31.00 and gave the stock an "overweight" rating in a research note on Monday, May 11th. Zacks Research lowered shares of Monte Rosa Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, February 4th. Finally, Weiss Ratings upgraded shares of Monte Rosa Therapeutics from a "sell (d-)" rating to a "sell (d)" rating in a research note on Monday, May 11th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $32.50.
View Our Latest Analysis on GLUE
About Monte Rosa Therapeutics
(
Get Free Report)
Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.
The company's main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
